CDMO Market Insight, Pricing and Benchmarking Reports
NICE INSIGHT REPORT

Messenger Ribonucleic Acid, mRNA:2024 Market Insight, CDMO Pricing and Competitor Benchmarking

Published May 2024
  • 2024 mRNA manufacturing pricing study—the first of its kind
  • Survey of clinical trials currently being conducted, segmented by type and treatment
  • SME analysis and forecasts of biotech fundraising
  • 68 CDMO profiles, including mRNA, chemically synthesized RNA, and LNP manufacturers
  • mRNA vaccines and therapeutic manufacturing challenges and innovations
Request A Sample

Key market insights for innovators, CDMOs and investors in the mRNA industry.

Essential price benchmarking and market intelligence for CDMOs

Essential price benchmarking and market intelligence for CDMOs

Compare prices to your competitors with our strategic pricing study, which breaks down the manufacturing process and industry costs. As investments pour in from both the private and government sectors, learn from leaders in mRNA-based drugs so you can better position your business.

Grasp the mRNA Vaccine & Therapeutics Pipeline

Grasp the mRNA Vaccine & Therapeutics Pipeline

Our Market Analysis provides an in-depth R&D pipeline report segmented by indication and development stage. Make informed business decisions with our guide to approved mRNA drugs and the developmental and clinical landscape. See where your competitors are from pre-clinical through Phase III trials.

Published May 2024

Our Market Analysis combines data insights and interviews with prominent mRNA players so your sales team can unlock the booming industry.

The Messenger Ribonucleic Acid, mRNA: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking provides

Strategic pricing study
Strategic pricing study that analyzes the manufacturing process and primary data
Over 60 CDMO profiles
Over 60 CDMO profiles which include segment, proprietary technologies and location
Market intelligence
Market intelligence segmented by drug type and disease application
Pipeline development mapping
Pipeline development mapping for approved mRNA drugs and preclinical through phase III trials
Investor insights
Investor insights for one of the fastest growing markets in pharma
Unique benefits and complexities
Unique benefits and complexities to mRNA manufacturing that is invaluable to developers

Over 900 hours of data collection and analysis, with

invaluable insights from industry experts

Table of Contents

Executive Summary